The SK Biopharmaceuticals and Ono licensing deals provide substantial non-dilutive capital that extends Biohaven's runway well into 2027 and validates its platforms. The key near-term catalysts are the RISE 3 topline data for opakalim (2H 2026), resolution of the partial clinical hold, and the FDA advisory committee meeting for Vyglxia in SCA. Monitor the SKBP closing conditions and the outcome of the nonclinical metabolite studies.
Price Chart
Executive Summary
Biohaven reported Q3 2026 results with a net loss of $129.3M ($0.86 GAAP EPS), narrower than the $173.4M loss in Q3 2025. The headline event is two major licensing deals: a global license with SK Biopharmaceuticals for the Kv7 platform providing $400M in near-term cash, and a regional license with Ono Pharmaceutical for the MoDE IgG degrader portfolio providing up to $100M in near-term payments. These deals provide substantial non-dilutive capital and validate the platforms, but the FDA partial clinical hold on new enrollment for opakalim (BHV-7000) adds uncertainty to the epilepsy program.
Key Financial Metrics
Key Facts
- Exclusive global license with SK Biopharmaceuticals for Kv7 ion channel platform including opakalim, providing $400M in near-term cash consideration ($350M at closing, $50M after one year)
- Exclusive license with Ono Pharmaceutical for MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and ASEAN, providing up to $100M in near-term payments ($80M upfront received, $20M milestone within a year)
- FDA accepted NDA resubmission for Vyglxia (troriluzole) in SCA with user fee goal date in Q1 2027
- FDA partial clinical hold on new enrollment for opakalim (BHV-7000) due to insufficient information on a rodent metabolite; RISE 3 topline data still on track for 2H 2026
- Cash position of $164.0M as of September 30, 2026, plus $80M received from Ono on October 20 and $350M expected from SKBP upon closing
- Q3 2026 net loss of $129.3M ($0.86 GAAP EPS) vs $173.4M ($1.64) in Q3 2025; non-GAAP adjusted net loss of $110.7M ($0.73) vs $155.9M ($1.47)
- R&D expenses decreased to $101.9M from $141.2M year-over-year due to strategic reprioritization
Financial Impact
Up to $500M in near-term cash from licensing deals ($400M from SKBP, $100M from Ono), plus milestone payments and royalties
Risk Factors
- FDA partial clinical hold on opakalim new enrollment pending nonclinical metabolite data; significance to humans is uncertain
- SKBP license closing conditions not yet completed (HSR waiting period expired October 28, 2026)
- Clinical-stage biotech with no approved products and history of net losses
- Vyglxia (troriluzole) NDA resubmission faces FDA advisory committee review
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001935979-26-000093 |
| Document: bhvn-20261029.htm | 0001935979-26-000093 |
| Document: 0001935979-26-000093-index-headers.html | 0001935979-26-000093 |
| Document: 0001935979-26-000093-index.html | 0001935979-26-000093 |
| Document: 0001935979-26-000093.txt | 0001935979-26-000093 |
| 8-K Data (Synthetic) | 0001935979-26-000093 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $16.49 | awaiting T+5 | awaiting T+5 | $15.42 (−6.49%) |
Oct 22, 2026 10d ago | 8-K | $14.69 $16.12 | ▲ +9.73% | ▲ +9.03% | $15.42 (+4.97%) |
Oct 15, 2026 17d ago | 8-K | $10.78 $13.88 | ▲ +28.76% | ▲ +29.19% | $15.42 (+43.04%) |
Sep 9, 2026 7w ago | 8-K | $12.79 $13.89 | ▼ −8.60% | ▼ −9.10% | $15.42 (−20.56%) |
Aug 26, 2026 9w ago | 8-K | $16.95 $15.69 | ▼ −7.43% | ▼ −7.31% | $15.42 (−9.03%) |
Aug 10, 2026 11w ago | 8-K | $14.49 $13.57 | ▼ −6.35% | ▼ −5.95% | $15.42 (+6.42%) |
Jul 9, 2026 16w ago | 8-K | $15.55 $14.17 | ▼ −8.87% | ▼ −8.31% | $15.42 (−0.84%) |
May 27, 2026 22w ago | 8-K | $10.24 $11.40 | ▲ +11.33% | ▲ +11.01% | $15.42 (+50.59%) |
May 4, 2026 25w ago | 424B5 | $9.71 $9.20 | ▲ +5.25% | ▲ +7.24% | $15.42 (−58.81%) |
May 4, 2026 25w ago | S-3ASR | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $15.42 (+58.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers